Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS001 + Chemotherapy in Gastric Cancer
NCT04744649Phase 2Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Mar 2021
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of toripalimab in gastric cancer (GC) and esophagogastric junction cancer (3 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Major Pathologic Response at 14 weeks. Status: unknown.
02
Drugs
toripalimab
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on NCT04744649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04744649.